Literature DB >> 26960133

Viral protein requirements for assembly and release of human parainfluenza virus type 3 virus-like particles.

Megan K Bracken1, Brandon C Hayes1, Suresh R Kandel1, Deja Scott-Shemon1, Larissa Ackerson1, Michael A Hoffman1.   

Abstract

To understand the roles of human parainfluenza virus 3 (HPIV3) proteins in assembly and release, viral proteins were expressed individually and in combination in 293T cells. Expression of the matrix (M) protein triggered release of enveloped, matrix-containing virus-like particles (VLPs) from cells. When M was co-expressed with the nucleocapsid (N), fusion (F) or haemagglutinin-neuraminidase (HN) proteins, VLPs that contained M+N, M+F and M+HN, respectively, were generated, suggesting that M can independently interact with each protein to facilitate assembly and release. Additionally, expression of N protein enabled incorporation of the phosphoprotein (P) into VLPs, likely due to known N-P interactions. Finally, the HPIV3 C protein did not enhance VLP release, in contrast to observations with the related Sendai virus. These findings reinforce the central importance of the M protein in virus assembly and release, but also illustrate the variable roles of other paramyxovirus proteins during these processes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26960133      PMCID: PMC5042090          DOI: 10.1099/jgv.0.000449

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  28 in total

1.  Requirements for budding of paramyxovirus simian virus 5 virus-like particles.

Authors:  Anthony P Schmitt; George P Leser; David L Waning; Robert A Lamb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  AIP1/Alix is a binding partner of Sendai virus C protein and facilitates virus budding.

Authors:  Takemasa Sakaguchi; Atsushi Kato; Fumihiro Sugahara; Yukie Shimazu; Makoto Inoue; Katsuhiro Kiyotani; Yoshiyuki Nagai; Tetsuya Yoshida
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Role of matrix and fusion proteins in budding of Sendai virus.

Authors:  T Takimoto; K G Murti; T Bousse; R A Scroggs; A Portner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state.

Authors:  D Garcin; P Latorre; D Kolakofsky
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein.

Authors:  Achut G Malur; Santanu Chattopadhyay; Ratan K Maitra; Amiya K Banerjee
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses.

Authors:  B Gotoh; K Takeuchi; T Komatsu; J Yokoo; Y Kimura; A Kurotani; A Kato; Y Nagai
Journal:  FEBS Lett       Date:  1999-10-08       Impact factor: 4.124

Review 7.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

8.  Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Authors:  Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

9.  Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

Authors:  Xiaoyan Zhan; Karen S Slobod; Sateesh Krishnamurthy; Laura E Luque; Toru Takimoto; Bart Jones; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2008-05-01       Impact factor: 3.641

10.  Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles.

Authors:  Ming Li; Phuong Tieu Schmitt; Zhuo Li; Thomas S McCrory; Biao He; Anthony P Schmitt
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

View more
  4 in total

1.  Paramyxovirus-Like Particles as Protein Delivery Vehicles.

Authors:  Santosh Panthi; Phuong Tieu Schmitt; F Jeffrey Lorenz; Brent A Stanfield; Anthony P Schmitt
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

Review 2.  Virus-like particle vaccines: immunology and formulation for clinical translation.

Authors:  Braeden Donaldson; Zabeen Lateef; Greg F Walker; Sarah L Young; Vernon K Ward
Journal:  Expert Rev Vaccines       Date:  2018-09-19       Impact factor: 5.217

3.  Identification of the Functional Domain of HPIV3 Matrix Protein Interacting with Nucleocapsid Protein.

Authors:  Xichuan Deng; Chaoliang Zhang; Kehan Zhang; Nan Lu; Yonglin He; Jia Liu; Zhibang Yang; Guangyuan Zhang
Journal:  Biomed Res Int       Date:  2020-12-08       Impact factor: 3.411

Review 4.  More Than Just a Barrier: The Immune Functions of the Airway Epithelium in Asthma Pathogenesis.

Authors:  Andreas Frey; Lars P Lunding; Johanna C Ehlers; Markus Weckmann; Ulrich M Zissler; Michael Wegmann
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.